Summary

The 7 major catheter-related bloodstream infections (CRBSIs) markets reached a value of US$ 988.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1508.8 Million by 2034, exhibiting a growth rate (CAGR) of 3.92% during 2024-2034.

The Catheter-Related Bloodstream Infections (CRBSIs) market has been comprehensively analyzed in IMARC’s new report titled “Catheter-Related Bloodstream Infections (CRBSIs) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. A catheter-related bloodstream infection (CRBSI) refers to a primary bloodstream infection resulting from the presence of an intravascular catheter, typically an arterial catheter or a central venous catheter. It is generally caused by nosocomial bacteremia and is one of the most frequent, lethal, and expensive problems associated with central venous catheterization. Some of the commonly observed signs and symptoms of catheter-related bloodstream infections comprise of inflammation or purulence at the catheter site, along with the acute onset of fever, chills, and hypotension with no apparent source of infection apart from the catheter. The diagnostic tests for vascular catheter-related infection can be performed if there is a high index of suspicion. Infections associated with catheters can be most accurately diagnosed using quantitative blood cultures.

The rising prevalence of hospital-acquired infections and the elevating incidences of improper aseptic procedures are primarily driving the catheter-related bloodstream infections (CRBSIs) market. In line with this, the expanding presence of patient-related factors, such as compromised integrity of the skin, increasing severity of the illness, the occurrence of distant infections, etc., is also bolstering the market growth. Moreover, the widespread adoption of a combination of salvage therapy with intravenous antibiotics and antibiotic lock therapy for patients with limited vascular access is further acting as a significant growth-inducing factor. Apart from this, several key players are making extensive investments in developing preventive solutions comprised of an anti-coagulant and broad-spectrum antimicrobial combination to decrease the threat of infection and blood clots. This, in turn, is also creating a positive outlook for the market. Additionally, various technological advancements related to accurate blood culture testing for early and effective disease diagnosis are further propelling the market growth. Inaccurate diagnostics have serious consequences, including procedure difficulties that increase the rate of morbidity and mortality. Numerous other factors, such as the continuous upgradation of healthcare infrastructures and the inflating penetration of refurbishment policies, are expected to drive the catheter-related bloodstream infections (CRBSIs) market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the Catheter-Related Bloodstream Infections (CRBSIs) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Catheter-Related Bloodstream Infections (CRBSIs) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Catheter-Related Bloodstream Infections (CRBSIs) market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Catheter-Related Bloodstream Infections (CRBSIs) market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Catheter-Related Bloodstream Infections (CRBSIs) market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Catheter-Related Bloodstream Infections (CRBSIs) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the Catheter-Related Bloodstream Infections (CRBSIs) market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Catheter-Related Bloodstream Infections (CRBSIs) market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Catheter-Related Bloodstream Infections (CRBSIs) market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the size of the Catheter-Related Bloodstream Infections (CRBSIs) patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Catheter-Related Bloodstream Infections (CRBSIs)?
What will be the growth rate of patients across the seven major markets?

Catheter-Related Bloodstream Infections (CRBSIs): Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Catheter-Related Bloodstream Infections (CRBSIs) drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Catheter-Related Bloodstream Infections (CRBSIs) market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Catheter-Related Bloodstream Infections (CRBSIs) - Introduction
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034​)
4.3 Market Overview (2018-2023) and Forecast (2024-2034​)
4.4 Competitive Intelligence

5 Catheter-Related Bloodstream Infections (CRBSIs) - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Catheter-Related Bloodstream Infections (CRBSIs) - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034​)

8 Catheter-Related Bloodstream Infections (CRBSIs) - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Catheter-Related Bloodstream Infections (CRBSIs) - Unmet Needs

10 Catheter-Related Bloodstream Infections (CRBSIs) - Key Endpoints of Treatment

11 Catheter-Related Bloodstream Infections (CRBSIs) - Marketed Products
11.1 List of Catheter-Related Bloodstream Infections (CRBSIs) Marketed Drugs Across the Top 7 Markets
11.1.1 Neutrolin - CorMedix Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Catheter-Related Bloodstream Infections (CRBSIs) - Pipeline Drugs
12.1 List of Catheter-Related Bloodstream Infections (CRBSIs) Pipeline Drugs Across the Top 7 Markets
12.1.1 Disodium edetate - Citius Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Catheter-Related Bloodstream Infections (CRBSIs) - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Catheter-Related Bloodstream Infections (CRBSIs) - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034​)
14.2.2 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034​)
14.3 Market Scenario - United States
14.3.1 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034​)
14.3.2 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034​)
14.3.3 Catheter-Related Bloodstream Infections (CRBSIs) - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034​)
14.4.2 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034​)
14.4.3 Catheter-Related Bloodstream Infections (CRBSIs) - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034​)
14.5.2 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034​)
14.5.3 Catheter-Related Bloodstream Infections (CRBSIs) - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034​)
14.6.2 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034​)
14.6.3 Catheter-Related Bloodstream Infections (CRBSIs) - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034​)
14.7.2 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034​)
14.7.3 Catheter-Related Bloodstream Infections (CRBSIs) - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034​)
14.8.2 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034​)
14.8.3 Catheter-Related Bloodstream Infections (CRBSIs) - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034​)
14.9.2 Catheter-Related Bloodstream Infections (CRBSIs) - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034​)
14.9.3 Catheter-Related Bloodstream Infections (CRBSIs) - Access and Reimbursement Overview

15 Catheter-Related Bloodstream Infections (CRBSIs) - Recent Events and Inputs From Key Opinion Leaders

16 Catheter-Related Bloodstream Infections (CRBSIs) Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats

17 Appendix